跳至主要内容
临床试验/NCT00530595
NCT00530595已完成不适用

Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Saitama Medical University0 个研究点开始时间: 2007年9月17日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成

研究概览

简要总结

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 30 to 80 years of age
  • Receiving hemodialysis at least 12 months and less than 5 years
  • Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

排除标准

  • Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

研究者

申办方类型
Other

相似试验

Effects of Angiotensin Receptor Antagonist on... | 临床试验